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The payment of clinical trial participants is contentious, 
particularly within a developing world context. The dividing 
line between ‘fair compensation’ and ‘undue inducement’ 
is difficult to determine. Two years ago, the Sunday Times 
highlighted this issue and sparked considerable debate in their 
article ‘Girls bunk school to cash in on HIV trials: School kids 
offered money to test gel product each time they have sex’. 
(This was a microbicide gel HIV prevention study.) The ‘cash’ 
given to study participants was the Medicines Control Council 
(MCC) R150.00 travel reimbursement requirement for all South 
African clinical trial participants, irrespective of the clinical 
nature and context of the study. This somewhat infamous 
sum of R150 was hotly debated in research ethics committees 
around the country, and became a bone of contention between 
sponsors (who wished to comply with the MCC and get on 
with the trial) and ethics committees who often regarded 
the amount as inappropriate and amounting to ‘undue 
inducement’. Recently, the MCC appears to be more flexible in 
the application of this rule; however, its legacy still holds sway.
Burgess, Sulzer and Emanuel (published in this issue of 
the SAMJ)1 investigated patients’ perspectives on clinical trial 
participation and the issue of payment. Their patients were 
from a low- to middle-income peri-urban group, with 60% 
able to attend study visits using a private car. The majority 
of participants felt that they should be reimbursed for travel 
costs. However, most participants believed that the R150 did 
not influence them to distort information in order to gain 
admission to the study, and most participants stated that 
they would have participated anyway, even if no payment 
were offered. Their study provides valuable insights into this 
ongoing debate, and needs to be repeated across the country. 
The opinion by participants that they should at least be paid 
for travel expenses is echoed internationally.2
Clarifying what the concept of ‘participant remuneration’ 
means for a particular clinical trial is important. Does it mean 
payment for expenses such as travel and meals; payment 
for time, inconvenience and recognition of effort; or overt 
inducement?2 When, if ever, is each category of reimbursement 
appropriate, or when does it amount to covert inducement? 
Payment for expenses incurred seems to be generally accepted. 
However, payment for time, inconvenience and recognition of 
a contribution is far more contentious, and it is more difficult 
to quantify what monetary value would be appropriate. The 
third category of payment, i.e. an inducement to participate, 
is widely regarded by the South African research ethics 
committee fraternity as not acceptable, because it may 
influence and undermine a participant’s autonomy and 
ability to consent freely to participation. This is particularly 
important when a study involves more than minimal risk, or a 
risk/benefit ratio that is equivocal. I suggest that there may be 
occasions when some form of overt inducement, monetary or 
otherwise, may be appropriate.
The spectrum of clinical trials conducted in South Africa 
is extensive and includes industry-sponsored trials and 
investigator-initiated, grant-funded research. Clinical trial 
sites occur across the spectrum of health care in South Africa. 
Trial participants, too, range from the more affluent users 
of private health care facilities, to impoverished rural and 
peri-urban communities. This debate is often assumed to 
apply largely to industry-sponsored clinical trials and their 
spectrum of participants. However, any blanket decision by 
a regulatory authority regarding payment to participants 
applies to all clinical trials, including grant-funded studies 
that address important public health care issues such as HIV 
and TB. The value and meaning for an executive of a R150 
payment to participate in a study differs completely from that 
of an unemployed, single mother living in a rural area for 
similar participation. The fact that R150 is almost equivalent 
to the monthly government childcare subsidy highlights this 
discrepancy.
The demographic characteristics of participants and the 
nature of clinical trials vary widely. Some trials are relatively 
low risk with good prospects of directly benefiting the 
participant. Others are higher risk, and yet others may have 
little prospect of direct benefit although they may contribute to 
knowledge or the common good. These factors must be taken 
into consideration when deciding whether or not some form of 
payment should be made to clinical trial participants. Another 
issue that should be considered is the notion of the ‘therapeutic 
misconception’ – the idea that many trial participants do not 
distinguish clearly between medical treatment and research. 
Appropriate payment of trial participants in such situations 
may reduce the ‘therapeutic misconception’ and increase 
participant autonomy.3
The MCC ‘R150 rule’ applies to investigator-driven grant-
funded research and industry-sponsored research. These 
studies often address very important public health care issues 
that are sometimes ignored by the pharmaceutical industry. 
They are funded by government institutions and foundations, 
often on shoe-string budgets. A recent study conducted in a 
tertiary academic hospital involving patients receiving chronic 
haemodialysis almost had to be abandoned because of the 
MCC’s insistence on the universal application of the ‘R150 
rule’, which added a further R48 000 to the limited study 
budget. A trial enrolling 300 participants over a period of 
2 years, with 10 study visits per participant, would require 
an extra R450 000 just to remunerate participants. While the 
reimbursement of actual travel costs and meals is an accepted 
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norm, important non-industry-sponsored research may go 
unfunded if there is no ‘negotiating space’ to determine 
fair reimbursement of the study-related costs incurred by 
participants.
A flip side to the above argument is minimal-risk research 
that may potentially have significant positive public health 
impact and influence policy. In such circumstances, a payment 
specifically to induce participation may be warranted, and 
would need to be evaluated case by case. This controversial 
assertion will almost certainly be challenged. However, 
consider the large-cluster randomised TB chemoprophylaxis 
study currently being conducted in the South African mining 
industry.4 This study is investigating the impact, at community 
level, on the prevalence rates of tuberculosis in miners, when 
INH chemoprophylaxis is administered to the employees 
of entire mine shafts. As the HIV-tuberculosis epidemic is 
devastating communities across sub-Saharan Africa, such a 
study has the potential to radically change policy and save 
lives. However, for it to be successful, a high recruitment 
rate per shaft is essential. Failure to achieve almost complete 
coverage may jeopardise study outcomes and result in a 
waste of valuable resources and opportunity. Currently, the 
ethically approved recruitment strategy involves offering 
small gift incentives, such as a cap or T-shirt, at intervals 
over the course of the study. The total combined monetary 
value of these incentives per participant is about R150.00. 
However, such a study (where high levels of community 
participation are critical for the integrity of the study) may 
present an opportunity to re-examine entrenched ethical norms 
related to payment for the purposes of covert inducement to 
participate and remain in the study. The development of trial 
site community advisory boards may be invaluable in assisting 
researchers and ethics committees to determine what sort of 
remuneration is appropriate for a given set of clinical trial- and 
participant-related circumstances.5
In conclusion, a one-size-fits-all approach to payment of 
clinical trial participants is injudicious. Whether or not any 
form of payment should be offered to participants is contingent 
on many factors, such as the nature of the study, degree of risk 
involved, profile of participants, funding source, and issues 
related to the potential public health implications of the study. 
Participant remuneration should be evaluated on a study-by-
study basis. The principal investigator and sponsor should 
discuss participant remuneration in the protocol. However, the 
final decision should be made, after careful consideration of 
all factors, by the research ethics committee that reviews and 
approves the study.
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